Sanofi’s SNY most important medicine remains its immunology drug, Dupixent, which continues to be the company’s primary growth engine. Dupixent sales represented roughly 42% of Sanofi’s first-half 2026 revenues.
Sanofimarkets Dupixent in partnership with Regeneron REGN. While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
At the same time, Sanofi is seeing a good uptake of its new medicines like novel recombinant factor VIII therapy, Altuviiio, and cancer drugs, Ayvakit and Sarclisa, which are important for broadening the company’s growth base.
Sales of its new and acquired drugs rose 48.3% at constant exchange rates to €1.3 billion in the second quarter, led by Altuviiio, Ayvakit and Sarclisa. Altuviiio achieved blockbuster sales in 2025. Ayvakit, added from the Blueprint Medicines acquisition, is expected to become the next blockbuster drug in 2026. Beyfortus (in partnership with AstraZeneca [AZN]) achieved blockbuster sales in its first full year of sales in 2024 and continues its expansion into new geographies.
Some other new products approved in the past couple of years include Wayrilz (rilzabrutinib), for immune thrombocytopenia, and Qfitlia (fitusiran), to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A and B. Cenrifki (tolebrutinib) was approved for treating non-relapsing secondary progressive multiple sclerosis in the EU in June 2026, while in the United States, Sanofi’s regulatory application seeking approval of tolebrutinib was issued a complete response letter in December 2025. Sanofi’s new drug application seeking approval for venglustat for Gaucher Disease is under FDA’s priority review, with a decision expected in November. Venglustat is also under regulatory review in the EU.
The newer medicines should become an increasingly important contributor to Sanofi’s revenue growth in the coming quarters, even as Dupixent remains the largest driver. Sanofi now expects its Pharma launches to generate approximately €10 billion of annual sales by 2030, compared with about €25 billion for Dupixent. This suggests the company is positioning Altuviiio, Ayvakit, Sarclisa and other newer medicines to gradually broaden its revenue base and reduce reliance on Dupixent over the longer term.
SNY’s Price, Valuation & Estimate Movement
Sanofi stock has plunged 15.5% year to date against an appreciation of 11.7% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Sanofi appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 7.82 forward earnings, lower than 18.08 for the industry. The stock is also trading below the stock’s 5-year mean of 11.11. The stock is much cheaper than most large drugmakers like Eli Lilly LLY, Novo Nordisk, AstraZeneca AZN, J&J, Merck, AbbVie and others.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has risen from $4.96 per share to $5.07 per share over the past 60 days.For 2027, earnings estimates have risen from $5.18 per share to $5.29 per share over the same timeframe.
Image Source: Zacks Investment Research
Sanofi has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).